Podcasts

Episode 50: Encountering Gender Differences: Women and PD Initiative

Given the differences women may encounter when dealing with their Parkinson’s Disease (PD), the Parkinson’s Foundation is leading the first national effort to address gender disparities in Parkinson’s research and care as part of an overall Women and PD Initiative. The Women and PD Teams to Advance Learning and Knowledge project (Women and PD TALK, for short) aims to develop new patient-centered recommendations to improve the health of women living with PD.

Over the two-year term of the project, a national network of ten sites is engaging experts in the patient, research, and health care communities to identify women’s needs, prioritize solutions, and create the recommendations. Using these insights, the Parkinson’s Foundation and leadership teams will develop action plans to improve Parkinson’s care for women. In this podcast, Megan Feeney, a Senior Manager in the Community Engagement Department of the Parkinson’s Foundation, and Jessica Shurer, Clinical Social Worker and Center Coordinator of the Parkinson’s Foundation Center of Excellence at the University of North Carolina in Chapel Hill, discuss the reasons for the project, the personnel involved in it, how it will run, and its goals. While the project is just starting, it is already producing actionable insights.

Released: March 12, 2019

Podcasts

Episode 49: Parkinson’s Disease vs. Parkinsonism: What’s the Difference?

If a person develops symptoms of tremor, slow movements, and stiffness, it could be early signs of Parkinson’s disease (PD) but it may also be the beginnings of any of a group of conditions known by the general term “parkinsonism,” conditions that have some symptoms in common with PD but differ in important ways. Also called atypical Parkinson’s disease or Parkinson’s plus, they tend to progress faster, and they may or may not respond to levodopa, and possibly only show modest benefit. While Parkinson’s disease represents 85-90% of all cases of parkinsonism, a definitive diagnosis for atypical parkinsonism may never be made while the person is alive. Licensed Clinical Social Worker Paula Wiener, a Senior Parkinson’s Information Specialist with the Parkinson’s Foundation, describes the difference between Parkinson’s disease and parkinsonism and gives some examples of Parkinson’s plus. As with PD, exercise is highly recommended for these atypical parkinsonian syndromes.

Released: February 26, 2019

Podcasts

Episode 45: Patient Engagement in Research: The Parkinson’s Advocates in Research Program (PAIR)

Medical research is a long and complicated process. Discovering the underlying causes of Parkinson’s Disease (PD), finding new treatments, or searching for a cure involves laboratory work, animal testing, and clinical trials with control subjects and then people with Parkinson’s. One important way to facilitate that research is to involve people affected by PD. The Parkinson’s Advocates in Research program (PAIR) at the Parkinson’s Foundation trains people with PD and caregivers to become involved in the research process, advising researchers on the important topics and helping design successful clinical trials without being overly burdensome to people participating in the trials. In this podcast, Karlin Schroeder, Director of Community Engagement at the Parkinson’s Foundation, and Kevin Kwok, a Research Advocate in the PAIR program, describe the program, its aims, and how to get involved for anyone wishing to become an advocate.

Released: January 1, 2019

Podcasts

Episode 39: PD Across Race & Ethnicity: Outreach to the African American Community

While Parkinson’s disease (PD) affects all races and ethnicities, not all communities recognize the disease equally. There is a perception in the African American community of PD as a disease attributed to older white men, and thus people may delay getting a diagnosis and help, leading to greater disability. These misperceptions may exist among healthcare professionals as well. Dr. Reversa Joseph, a movement disorders specialist and Adjunct Assistant Professor of Neurology at the Ohio State Wexner Medical Center, says one approach to this problem is outreach and education, particularly when it comes to recognizing early symptoms of the disease. She describes the perceptions in the community and her efforts to raise awareness of PD.

Released: October 9, 2018

Podcasts

Episode 38: More Than a Movement Disorder: Addressing Mood and Coping

Parkinson’s disease (PD) is more than a movement disorder. While motor symptoms may be a prominent outward symptom of PD, mood and other emotional changes are also common- and not just for the person with PD. Their care partners may also experience such changes. Often, the best way to recognize these problems and figure out coping strategies may involve other health professionals in addition to a movement disorders physician, such as social workers or psychologists. Licensed Clinical Social Worker Jessica Shurer is the center coordinator of the Parkinson’s Foundation Center of Excellence at the University of North Carolina, Chapel Hill, where a team of health professionals is available to people with Parkinson’s. She discusses the emotional changes that may occur throughout the course of the disease along with suggestions for how people who are unable to travel to large medical centers may find help to address their emotional needs.

Released: September 25, 2018

Podcasts

Episode 35: Preclinical Models of PD

Before therapies make it into clinical trials, they undergo a series of laboratory testing. These preclinical models of the disease may include animals, cell lines, or single cell organisms to help validate the success of a potential treatment. Additionally, preclinical models of Parkinson’s disease may help us to understand the mechanisms and the molecular or genetic pathways that control or interfere with normal and abnormal functions. Understanding the underlying disease processes is critical to targeting molecular and cellular pathways for the development of therapies. Richard Smeyne is a professor of neuroscience and director of the Jefferson Comprehensive Movement Disorder and Parkinson’s Center at Thomas Jefferson University in Philadelphia. His laboratory focuses on mechanisms of neurodegeneration and neuroprotection. In this podcast, he discusses the value of research on preclinical models of PD.

Released: August 14, 2018

Podcasts

Episodio 16: Correlación entre cultura, idioma y opciones de tratamiento en el Parkinson

Entender si existe una correlación entre cultura, idioma y opciones de tratamiento en el Parkinson nos ayuda a saber cómo se comunica la información de la enfermedad entre los hispanohablantes (desde las opciones quirúrgicas hasta la información general de la enfermedad).

En este episodio, hablamos acerca de la neuropsicología, la familia y la cultura en la medicina con el doctor Xavier E. Cagigas, director asociado del Centro de Excelencia Neuropsiquiátrico para Hispanos de UCLA y profesor clínico asistente de ciencias de la salud en el departamento de Psiquiatría y Ciencias Bioconductuales en la University of California, Los Ángeles, UCLA.

El doctor Cagigas comparte su experiencia con los programas culturales de neuropsicología y la correlación entre cultura, idioma y opciones de tratamiento en el Parkinson.

Lanzado: 1 de febrero de 2022

Podcasts

Episode 34: New Pathways & Drug Development

Developing medical treatments today for the most part depends on identifying a problem, whether it is physical, metabolic, behavioral or psychological and then targeting a treatment for that problem. Knowing what process causes a disease or symptom helps direct discovery of its potential treatments. In the case of Parkinson’s disease, modern techniques such as brain imaging, biochemical tests, and laboratory studies can reveal likely targets for designing new treatments. In this podcast, Michael Okun, National Medical Advisor of the Parkinson’s Foundation and Co-director of the University of Florida Movement Disorders Center, a Parkinson’s Foundation Center of Excellence, discusses Parkinson’s disease mechanisms as possible targets for drug development, where certain drugs stand now, and how the process of bringing a drug to market for PD may be sped up.

Released: July 31, 2018

Podcasts

Episode 15: Why and How to Participate in Parkinson’s Research

Clinical trials – research studies that involve people – are key to medical advances. But sometimes it is hard to recruit and enroll enough participants to make the results meaningful. It is important for people with Parkinson’s disease to participate in clinical trials to help researchers find better ways to treat, and hopefully slow down or even stop, Parkinson’s. Some trials are short, lasting only a few weeks, while some can take years, but all trials aim to produce results that will lead to better lives. Christine Hunter, a nurse and Parkinson’s Foundation Center of Excellence coordinator at Baylor College of Medicine in Houston, describes the value of volunteering for clinical trials and how participants view their experiences.

Released: November 7, 2017

Podcasts

Episode 33: The Parkinson’s Prevalence Project

The prevalence of Parkinson’s disease and parkinsonism has been on the rise since the 1970’s, but a true estimate of how many people are affected had been difficult to ascertain because of how we collected the early data. It is important to know the prevalence of the disease in order to allocate health care resources, including health care professional training as well as money for research into the conditions of PD. The Parkinson’s Foundation has taken a leading role in determining the prevalence of PD and related conditions in the North American population through the Parkinson’s Prevalence Project.

James Beck, vice president for scientific affairs and chief scientific officer of the Parkinson’s Foundation, says he believes the number of people living with Parkinson’s in the United States has been dramatically underestimated and does not represent the ethnic diversity of people affected due to the way in which we gathered older data. He explains how the Parkinson’s Prevalence Project is designed to give a clearer picture of PD in North America.

Back to Top